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mated quality-adjusted life-years (QALYs), number/costs of SREs, and drug/admin-
istration costs for mPC patients receiving denosumab or zoledronic acid for 27
months (trial timeframe) and 60 months. List prices were used in the base case. A
generic zoledronic acid price (53%  list price, per data for now-generic bisphos-
phonates) and discounted prices (–30%) were used for both denosumab and zole-
dronic acid in scenario analyses. Clinical inputs reproduced trial outcomes. QALYs
were estimated via utility weights to time spent in health states (no SRE; SRE;
post-SRE; death). SRE costs and utilities were literature-based. RESULTS: Over 60
months, denosumab resulted in fewer SREs (–0.398), more QALYs (0.0096), and
lower SRE-related costs (–£790). The costs/QALY (drug costs; total costs) over 60
months in the list price scenario (list price for both agents), in the generic zole-
dronic acid after May 2013 pricing scenario, and in the scenario with both agents
discounted after May 2013, were £164,502 (£2369; £1579), £214,707 (£2851;
£2061), and £98,124 (£1732; £942), respectively. Similar results were found over
27 months. CONCLUSIONS: The incremental cost/QALY gained with denosumab
versus zoledronic acid exceeded the traditional £30,000 threshold, thus raising
important questions about denosumab’s health-economic value in mPC.
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OBJECTIVES: Approximately 60% of breast cancer cases are a hormone sensitive.
Tamoxifen (TAM) is most widely used treatment of hormone-dependent breast
cancer. In the last decade, TAM has been surpassed by more effective, but more
expensive Aromatase Inhibitors (AI), new generation of estrogen inhibitors. In Can-
ada, mono and sequential strategies of AI and TAM for treating ER early breast
cancer patients are used widely. Meanwhile, practitioners have not come to a
consensus yet regarding the optimal cost-effective hormone therapy strategy. The
objective of study to assess cost-effectiveness of four hormone strategies (mono
and sequential TAM and AI) currently used for treating ER early breast cancer
patients from the Canadian health care perspective. METHODS: We performed a
cost-effectiveness analysis using a Markov model from a societal perspective with
a lifetime horizon. The base case involved 65-year-old ER hormone sensitive
women with early breast cancer. Probabilistic sensitivity analysis was used to in-
corporate parameter uncertainties. Expected value of perfect information was per-
formed to identify future research directions. Outcomes were quality-adjusted life
years (QALYs) and costs. RESULTS: AI-TAM sequential strategy is dominant be-
cause it is more effective and less costly. Next dominant strategy is TAM-AI, AI
monotherapy is more effective but more costly than standard TAM monotherapy.
AI monotherapy, TAM-AI and AI-TAM sequential therapies reduce recurrence by
8.1%, 5.9% and 5.6% compared to TAM monotherapy. Additional QALY gained from
using new therapies were 0.06 QALYs for AI, 0.08 QALY’s for TAM-AI and 0.16
QALYs for AI-TAM therapies. Using AI monotherapy increased total expected dis-
counted cost by CAD $302 per patient compared to TAM monotherapy, while using
sequential therapies reduced total cost by CAD $62 TAM-AI and CAD $481 for
AI-TAM. CONCLUSIONS: In postmenopausal ER women with hormone sensitive
early breast cancer, adjuvant AI-TAM sequential therapy may be cost effective
from the Canadian health care system perspective.
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OBJECTIVES: Effectiveness of rituximab maintenance treatment among patients
with relapsed follicular lymphoma (FL) has been established in a randomised trial
(EORTC20981). Although trials have been accepted as the golden standard for ef-
fectiveness, results might not be generalisable to real-world patient populations.
Therefore, outcomes research was conducted to calculate real-world cost-effec-
tiveness of second line rituximab maintenance compared to observation in FL
patients in the Netherlands. METHODS: Two Dutch population-based registries
(PHAROS and HemoBase), obtained data on patient characteristics, treatment, and
resource utilisation of patients diagnosed with FL in the past 20 years. Patients
responding to second line chemotherapy were included in the observation or
maintenance group. A Markov model was applied to calculate real-world
cost-effectiveness. RESULTS: Out of 735 FL patients included in the registries, this
study allocated 57 and 49 patients to the observation and maintenance group,
respectively. Median age was similar in both groups (61 years). Differences between
the groups were found for second line treatment with rituximab (77% and 92% in
the observation and maintenance group p0.05) and years since diagnosis
(p0.01). The maintenance group showed higher 3-year overall survival (75% ver-
sus 63%) and longer time till next treatment (p0.01). Compared to the trial, real-
world patients were older and less often diagnosed with stage IV. Real-world pre-
scription of rituximab was comparable to the trial although cycles were prescribed
more frequent. Daily practice data combined with trial efficacy resulted in cost-
effectiveness ratios between €3,614 and €5,246 per life year gained and €3,555 and
€5,156 per quality-adjusted life year. CONCLUSIONS: Real-world FL patients were
not identical to trial patients emphasising the importance of studying real-world
data. However, findings from non-randomised groups should be analysed with
caution, since observed dissimilarities between the groups suggested the represen-
tation of different types of patients. Nevertheless, real-world cost-effectiveness for
second line rituximab maintenance was favourable.
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OBJECTIVES: Maintenance treatment with Rituximab (MabThera) has been shown
a cost-effective and / or cost-saving treatment option, when compared with alter-
native treatment strategies for treating patients with Non-Hodgkins Lymphoma
(NHL) in several countries. The objective of this study is to identify whether main-
tenance with Rituximab in first line NHL patients represents a cost-effective treat-
ment option for the Greek Healthcare system. METHODS: A cost-effectiveness
Markov model that compared maintenance with Rituximab versus observation
was applied after adapting for local cost data from published sources. Clinical data
were derived from PRIMA and EORTC 20981. RESULTS: Patients treated with Ritux-
imab remained in Progression Free state for an additional 1.91 years and displayed
an additional 1.61 QALYs versus observation. Mean Total Cost per patient in the
Rituximab maintenance arm was calculated at €79,721 versus €67,928 in the obser-
vation arm. Mean total cost of PFS including the cost of Adverse Events was €71.95
for the Rituximab group and €57.44 for the observation group. Mean Supportive
Care costs for the Progression-Free state were € 18,193 for patients on Rituximab
and €20,168 for patients on observation. Mean supportive care cost of progression
was € 7,766 for the Rituximab group and €10,483 for the observation group. ICERs for
Rituximab maintenance were €8,679 per QALY gained and €7,866 per LYG gained,
which are both below the common cost-effectiveness thresholds used by Health
Technology Assessment (HTA) agencies worldwide. CONCLUSIONS: Maintenance
treatment with Rituximab is clinically more effective and economically more cost-
effective than existing treatments for patients with NHL in the Greek health care
setting. Full reimbursement of Rituximab maintenance treatment for patients with
NHL by Social Security Funds would constitute an effective use of their – scarce –
resources.
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OBJECTIVES: In the UK, prostate cancer is the most commonly-occurring cancer in
males; it has an incidence rate of 103 per 100,000. First-line therapy for patients
with advanced prostate cancer is commonly a luteinising hormone-releasing hor-
mone (LHRH) agonist. Degarelix is a testosterone-ablating therapy that acts as
gonadotrophin-releasing hormone (GnRH) antagonist. It induces a decrease in both
testosterone and prostate-specific antigen (PSA) levels, without the initial testos-
terone surge which can be associated with LHRH agonist therapies such as leupro-
relin, goserelin and triptorelin. A previous model assessing the cost-effectiveness
of degarelix was published by Lu et al (2011). However, only limited data were
available at the time and here we present a model based on longer term data.
METHODS: A cost-utility model using a cohort state transition structure was de-
veloped to assess the cost effectiveness of degarelix. The 5-year data informing the
model was derived from the Phase III clinical trials (CS21 and CS21a). Advisory
boards conducted with UK clinicians informed the model structure. Patients trans-
ferred through disease states according to their PSA progression – identified by
clinicians as a key indicator of progression to second-line treatment. Adverse
events for which there were statistically significant differences were also included
in the model. A scenario analysis was undertaken where PSA progression was
assumed to be equal for degarelix and leuprorelin, although data indicate a lower
risk with degarelix. RESULTS: Degarelix showed a reduction in costs (£5,152) and
increase in QALYs (0.24) when compared to leuprorelin in the base case. In the
scenario analysis, treatment with degarelix was also dominant. CONCLUSIONS:
Updated modelling undertaken with the most recent data indicates that treatment
with degarelix is dominant – this remains the case when it is conservatively as-
sumed, that PSA progression is not important, contrary to what was informed by
clinicians, and seen in the trial data.
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OBJECTIVES: Personalized medicine tries to select specific subpopulation of pa-
tients by biomarkers to refine therapeutic algorithms. We have performed a cost-
effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) per ra-
diological response (RR) for cetuximab or panitumumab based scheduled as 1st line
therapies for metastatic colorectal cancer (mCRC) patients in Spain. METHODS:
A421V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
Efficacy data were computed from all randomized trials (RT) that guided on-label
uses of bevacizumab (K-Ras mutated), panitumumab and cetuximab. Non- signif-
icant outcomes and toxicity as predictor of efficacy were excluded. Prices for drugs
in Spain were assumed to represent the best-value for each drug including all
possibilities to reduce pharmacy costs. For 1st line, median duration of therapy
reported by RT was used to calculate the final budget. 70kg and 1.7 m were used as
reference for patient dose calculations. RESULTS: We simulated 3 main scenarios
based on the possibilities of therapy for K-Ras wild type (wt) patients assuming that
all patients harboring a K-Ras mutated tumor received bevacizumab based chemo-
therapy. So, in scenario A K-Ras wt patients received weekly cetuximab combined
with FOLFOX, ORR reaches 54% and global cost per RR sums €20,026. Scenario B:
administering panitumumab-FOLFOX yields 51% ORR and € 19,861 per RR. Scenario
C: cetuximab biweekly combined with FOLFOX yields 54% and €19,726. ICER for
scenario A vs B is estimated at € 22,835 per additional response. ICER for scenario C
vs B is estimated at € 968 per additional response. CONCLUSIONS: First-line oxali-
patin combinations of cetuximab for wt and bevacizumab for mutated patients
optimize response rate rather than panitumumab and bevacizumab schedules.
Efficiency of this therapeutic approach could be improved with biweekly cetux-
imab administration. Marginal cost differences between cetuximab and panitu-
mumab therapies are exceeded by efficacy gap as measured by response rates in
RT.
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OBJECTIVES: An analysis recently evaluated hematologic responses among 126
Iraqi Ph CML-CP patients who were switched from Glivec (the beta crystalline
form of imatinib mesylate [IM]), to an alpha crystalline form, generic copy of ima-
tinib (IMgc). At the time of IMgc switch, patients had received IM for 50 months and
were at least in complete hematologic response (CHR). Three months post-switch,
18 (14%) and 4 (3%) patients progressed to accelerated phase (AP) and blast crisis
(BC), respectively. Six months post-switch, an additional 20 (16%) lost hematologic
response. A previously-published CML Markov model was adapted to compare over
50 years the projected life-years (LYs), progression-free life-years (PFLY), and qual-
ity-adjusted life-years (QALYs) of IM patients switched vs. not switched to IMgc.
METHODS: Patients entered the model after 50 months of IM therapy. At that time,
based on the IRIS trial results, patients were assumed to be distributed in CHR
(4.7%), partial (6.5%) and complete (88.9%) cytogenetic response. Patients remain-
ing on IM transitioned within these 3 responses levels and no hematologic re-
sponse, AP, BC, and death according to the original model probabilities. For pa-
tients switched to IMgc, transition rates were based exclusively on rates observed
in the Iraqi study (Scenario 1) or on the Iraqi study for the first 6 months and
thereafter on the original model (Scenario 2). Utilities were from the original model.
RESULTS: Patients remaining on IM were predicted to experience 15.71 LYs, 14.51
PFLYs, and 13.44 QALYs. Corresponding numbers for patients switched to IMgc
were 2.42 LYs, 1.13 PFLYs, 1.39 QALYs (in Scenario 1) and 11.44 LYs, 10.19 PFLYs, and
9.57 QALYs (in Scenario 2). Results were also sensitive to response distribution at
model entry. CONCLUSIONS: Switching from IM to an IMgc that does not have the
same properties may result in substantial loss of LYs, PFLYs, and QALYs.
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OBJECTIVES: Crizotinib, a tyrosine kinase anaplastic lymphoma kinase (ALK) in-
hibitor, represents a therapeutic alternative to patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) that are ALK. This study aimed to
estimate the cost-effectiveness of crizotinib in the treatment of this group of pa-
tients compared to currently available chemotherapy schemes:
gemcitabinecisplatin (GC), pemetrexedcisplatin (PC) and docetaxelcisplatin
(DC), from the Mexican public payer’s perspective. METHODS: A mutually exclu-
sive, four-state Markov model was developed: stable without progression, stable
with response to treatment, disease progression and death (monthly transitions,
six-year timeframe, 5% discount rate). The model assess life-years gained and
direct medical costs (pre-treatment, drugs costs, drug administration, monitoring
and adverse event management), per each treatment (basecase GC), in terms of
ICER. Effectiveness data was extracted from published literature. Drug costs and
medical resources were extracted from Instituto Mexicano del Seguro Social data-
base. Crizotinib’s cost were provided by manufacturer (not listed yet in Mexican
formulary) and are expressed in 2012 US$. Univariate sensitivity analyses regard-
ing monthly acquisition cost and clinical efficacy of crizotinib were performed.
RESULTS: Crizotinib was the most effective alternative with 3.02 life-years gained,
compared with 1.55, 1.74 and 1.34 for GC, PC and DC, respectively. The cost of GC
was $15,792.3, while the incremental cost for PC, DC and crizotinib were $10,787.4,
$13,171 and $61,895.3, respectively. DC was dominated, while ICER for PC and cr-
izotinib were $56,775.9 and $42,105.6, respectively, being crizotinib a cost-effective
alternative. Results were sensible to changes in acquisition cost of crizotinib and
less sensible to changes in the probabilities of death and disease progression with
crizotinib. CONCLUSIONS: From the Mexican public payer’s perspective, crizotinib
would represent an opportunity for both, this group of patients, and health care
institutions to achieve better clinical results than GC, PC and DC, as well as minor
cost regarding PC.
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OBJECTIVES: Breast-cancer is the most frequent malignancy amongst women in
Europe and therefore represents a major public-health problem. The purpose of
this analysis was to estimate the cost-effectiveness of AT (doxorubicin, docetaxel)
compared with AC (doxorubicin, cyclophosphamide), CMF (cyclophosphamide,
methotrexat, 5-fluoruracil) and FEC (5-fluoruracil, epirubicin, cyclophosphamide)
administered as adjuvant therapy to women with node-positive breast-cancer
across four European countries (Spain, Italy, Germany and Belgium). METHODS:
We developed a multi-country Markov-model to simulate the long-term conse-
quences from initiation of adjuvant chemotherapy over 10 years. The model sim-
ulates the incidence of complications during chemotherapy (febrile neutropenia,
chemotherapy-induced nausea/vomiting, dose-reduction, dose-delay, grade 3/4
adverse events) and long-term consequences like local or distant-relapse, acute
myelogenous leukemia (AML), chronic heart failure and death. Monte-Carlo-sim-
ulation accounted for uncertainty. The model includes twelve health-states. Prob-
abilities were derived from clinical and epidemiological studies; direct costs (2011)
from published sources from the payer’s perspective. QALYs, life-years (LYs) and
costs were discounted at 5% p.a. RESULTS: Over a 10-year timeframe, costs asso-
ciated with AC are 13,266€, 14,826€, 15,699€ and 16,558€ for Spain, Italy, Germany
and Belgium, respectively. AC is associated with 5.85 QALYs (6.49 LYs). Costs for AT
amount to 15,362€ (Spain), 19,004€ (Italy), 19,768€ (Germany) and 20,625€ (Belgium)
and AT delivers a similar benefit to AC: 5.85 QALYs (6.50 LYs). The resulting oppor-
tunities for cost-savings with AC vs. AT are between 2,096€ (Spain) and 4,178€
(Italy). Costs associated with CMF are 14,145€ (Spain), 15,609€ (Italy), 16,411€ (Ger-
many) and 16,924€ (Belgium); 5.8 QALYs (6.4 LYs) are gained. AC dominates CMF.
FEC associated total costs are 15,138€ (Spain), 15,652€ (Italy), 17,431€ (Germany) and
17,492€ (Belgium). QALYs are 6.03 (6.81 LYs). FEC dominates AT in all four countries.
CONCLUSIONS: Cyclophosphamide-based regimens (FEC, AC and CMF) demon-
strate a better performance from cost-effectiveness perspective vs. AT in the four
European countries.
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OBJECTIVES: Renal cell carcinoma (RCC) accounts for approximately 2% of all can-
cers worldwide. Many patients present with advanced or unresectable disease, and
up to 30% of patients treated by nephrectomy for localized disease will relapse.
Improved care for patients with metastatic RCC (mRCC), including targeted thera-
pies have improved prognosis but have also increased drug costs. In this study, we
set out to study costs and outcomes in mRCC treatment using national registries
comprising all patients diagnosed with RCC in Sweden. METHODS: Two cohorts of
patients diagnosed with mRCC 2002-2005 and 2006-2008, representing patients
diagnosed pre- and post-TKI introduction respectively, were identified in the na-
tional Swedish Cancer Registry. A pre-defined algorithm was used to determine the
presence of mRCC. Through record linkage with the national registries for drug
prescriptions, hospital care, and causes of death, data on resource utilization and
survival was obtained. The Kaplan-Meier method was used to estimate survival,
using an exponential model to calculate the mean for 4.5 years - beyond the end of
the observation period. Costs were estimated in 2010 SEK (1 SEK  USD ($) 0.14),
using the Lin method to account for censoring. Sensitivity analysis was done to
better incorporate the cost of hospital dispensed drugs. RESULTS: Patients diag-
nosed post-TKI introduction (n1,217) had longer survival (median 1.08 compared
to 0.79 years, restricted mean 1.73 compared to 1.55, both p  0.001) compared to
patients diagnosed pre-TKI introduction (n1,536). Costs were higher for patients
more recently diagnosed: $52,601 versus $40,970. Pharmaceutical costs were
$12,418 higher in the post period but where slightly offset by lower inpatient care
costs. The cost per life-year gained (LYG) amounted to $64,616.CONCLUSIONS:The
study suggests that mRCC survival has improved in recent years while costs have
increased, resulting in a fairly modest cost per LYG in a Swedish setting.
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